$NDRA
ENDRA Life Sciences Inc. Stock $ndra

$ndra Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000165495424003873 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.739M	$878.4K	$5.517M
YoY Change	12.34%	-46.76%	-16.45%
% of Gross Profit
Research & Development	$1.042M	$579.4K	$5.004M
YoY Change	-25.14%	-65.17%	-23.66%
% of Gross Profit
Depreciation & Amortization	$15.30K	$23.73K	$123.7K
YoY Change	-55.67%	-26.14%	28.0%
% of Gross Profit
Operating Expenses	$2.781M	$1.458M	$10.52M
YoY Change	-5.4%	-56.0%	-20.04%
Operating Profit	-$2.781M		-$10.52M
YoY Change	-5.4%		-20.04%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$4.841K	-$1.760K	$460.5K
YoY Change	-241.63%	-107.4%	-2238.53%
Pretax Income	-$2.776M	-$1.460M	-$10.06M
YoY Change	-5.68%	-55.63%	-23.67%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.776M	-$1.460M	-$10.06M
YoY Change	-5.68%	-55.63%	-23.67%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.26	-$0.17	-$1.58
COMMON SHARES
Basic Shares Outstanding	11.04M shares	8.455M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.135M	$2.834M	$2.834M
YoY Change	-51.82%	-42.04%	-42.04%
Cash & Equivalents	$1.135M	$2.834M
Short-Term Investments
Other Short-Term Assets	$135.8K	$198.9K	$198.9K
YoY Change	-68.31%	-79.97%	-79.97%
Inventory	$2.712M	$2.623M
Prepaid Expenses	$135.8K	$198.9K
Receivables
Other Receivables
Total Short-Term Assets	$1.271M	$3.033M	$3.033M
YoY Change	-76.98%	-64.43%	-64.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$111.5K	$465.9K	$465.9K
YoY Change	-51.14%	97.69%	-37.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.365M	$3.255M	$3.255M
YoY Change	667.68%	54284.56%	54248.25%
Total Long-Term Assets	$3.790M	$3.721M	$3.721M
YoY Change	233.71%	397.87%	397.86%
TOTAL ASSETS
Total Short-Term Assets	$1.271M	$3.033M	$3.033M
Total Long-Term Assets	$3.790M	$3.721M	$3.721M
Total Assets	$5.061M	$6.754M	$6.754M
YoY Change	-23.96%	-27.17%	-27.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$521.6K	$360.4K	$360.4K
YoY Change	-0.47%	-41.3%	-41.3%
Accrued Expenses	$695.1K	$514.2K	$514.2K
YoY Change	-45.66%	-51.55%	-51.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$28.48K	$28.48K
YoY Change	-100.0%	0.0%	0.0%
Total Short-Term Liabilities	$1.217M	$903.1K	$903.1K
YoY Change	-33.58%	-46.99%	-46.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$145.8K	$192.1K	$192.1K
YoY Change	-55.0%	-47.51%	-47.51%
Total Long-Term Liabilities	$145.8K	$192.1K	$192.1K
YoY Change	-55.0%	-47.51%	-47.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.217M	$903.1K	$903.1K
Total Long-Term Liabilities	$145.8K	$192.1K	$192.1K
Total Liabilities	$1.363M	$1.095M	$1.095M
YoY Change	-36.8%	-47.08%	-47.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$94.71M	-$91.93M
YoY Change	11.66%	12.29%
Common Stock	$1.092K	$1.039K
YoY Change	244.48%	227.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.698M	$5.659M	$5.659M
YoY Change
Total Liabilities & Shareholders Equity	$5.061M	$6.754M	$6.754M
YoY Change	-23.96%	-27.17%	-27.17%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.776M	-$1.460M	-$10.06M
YoY Change	-5.68%	-55.63%	-23.67%
Depreciation, Depletion And Amortization	$15.30K	$23.73K	$123.7K
YoY Change	-55.67%	-26.14%	28.0%
Cash From Operating Activities	-$2.144M	-$2.179M	-$9.549M
YoY Change	-14.46%	-29.46%	-25.22%
INVESTING ACTIVITIES
Capital Expenditures	$27.00K	$3.880K	$33.88K
YoY Change	0.0%	-89.94%	-83.28%
Acquisitions
YoY Change
Other Investing Activities	$3.200K	$9.160K	$9.160K
YoY Change
Cash From Investing Activities	-$23.80K	$5.280K	-$24.72K
YoY Change	-11.87%	-113.69%	-87.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$7.518M
YoY Change			-10.49%
Debt Paid & Issued, Net	$28.48K
YoY Change
Cash From Financing Activities	$468.9K	1.668M	7.518M
YoY Change			-10.49%
NET CHANGE
Cash From Operating Activities	-$2.144M	-2.179M	-9.549M
Cash From Investing Activities	-$23.80K	5.280K	-24.72K
Cash From Financing Activities	$468.9K	1.668M	7.518M
Net Change In Cash	-$1.699M	-505.2K	-2.055M
YoY Change	-32.94%	-83.85%	-55.05%
FREE CASH FLOW
Cash From Operating Activities	-$2.144M	-$2.179M	-$9.549M
Capital Expenditures	$27.00K	$3.880K	$33.88K
Free Cash Flow	-$2.171M	-$2.183M	-$9.583M
YoY Change	-14.31%	-30.21%	-26.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10390150	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3169103	shares
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management makes estimates that affect certain accounts including inventory reserve, deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.</p>
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001681682
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10390150	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3169103	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023	ndra	Expected Dividend Yield ExpectedDividendYield	0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37969
CY2023	dei	Entity Registrant Name EntityRegistrantName	ENDRA Life Sciences Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0579295
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3600 Green Court
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 350
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Ann Arbor
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48105-1570
CY2023	dei	City Area Code CityAreaCode	734
CY2023	dei	Local Phone Number LocalPhoneNumber	335-0468
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	NDRA
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	10256564	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11035659	shares
CY2023	dei	Auditor Firm AuditorFirmId	587
CY2023	dei	Auditor Name AuditorName	RBSM LLP
CY2023	dei	Auditor Location AuditorLocation	New York, NY
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2833907	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4889098	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	198905	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	490299	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3032812	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5379397	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2622865	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2644717	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	111782	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	235655	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	354091	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	505816	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	626610	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	502576	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	5986	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	5986	usd
CY2023Q4	us-gaap	Assets Assets	6754146	usd
CY2022Q4	us-gaap	Assets Assets	9274147	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	700754	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1523012	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	173857	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	152228	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	28484	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	28484	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	903095	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1703724	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	192062	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	365919	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	192062	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	365919	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1095157	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2069643	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1039	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	317	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	97582868	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	89068015	usd
CY2023Q4	ndra	Stock Payable StockPayable	5233	usd
CY2022Q4	ndra	Stock Payable StockPayable	6073	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91930152	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81869902	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5658989	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7204504	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6754146	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9274147	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5003695	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6554194	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	820554	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1429150	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4696486	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5174215	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	10520735	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	13157559	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-10520735	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-13157559	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	460485	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21533	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	460485	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-21533	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10060250	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13179092	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-10060250	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13179092	usd
CY2023	ndra	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-1.58
CY2022	ndra	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-4.56
CY2023	ndra	Weighted Average Number Of Common Share Outstanding Basic And Diluted WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted	6363759	shares
CY2022	ndra	Weighted Average Number Of Common Share Outstanding Basic And Diluted WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted	2891292	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10784246	usd
CY2022	ndra	Common Stock Issued For Cash Net Of Funding Costs Amount CommonStockIssuedForCashNetOfFundingCostsAmount	8399512	usd
CY2022	ndra	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	1199838	usd
CY2022	ndra	Stock Payable Towards Preference Dividend StockPayableTowardsPreferenceDividend	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13179092	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7204504	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7204504	usd
CY2023	ndra	Common Stock Issued For Cash Net Of Funding Costs Amount CommonStockIssuedForCashNetOfFundingCostsAmount	6483393	usd
CY2023	ndra	Common Stock Issued For Warrant Exercise Amount CommonStockIssuedForWarrantExerciseAmount	1014859	usd
CY2023	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	20053	usd
CY2023	ndra	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	996430	usd
CY2023	ndra	Stock Payable Towards Preference Dividend StockPayableTowardsPreferenceDividend	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-10060250	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5658989	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-10060250	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13179092	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	123726	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	96661	usd
CY2023	ndra	Fixed Assets Net Write Offs FixedAssetsNetWriteOffs	24868	usd
CY2022	ndra	Fixed Assets Net Write Offs FixedAssetsNetWriteOffs	1391	usd
CY2023	ndra	Inventory Reserve InventoryReserve	138045	usd
CY2022	ndra	Inventory Reserve InventoryReserve	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	996430	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1199838	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	151725	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	137597	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-167360	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-355128	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	116193	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1360139	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-822258	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	111575	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-152228	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-132330	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9548775	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12769371	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	33884	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	202577	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	9163	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24721	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-202577	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6483393	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8399512	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	20053	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1014859	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7518305	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8399512	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2055191	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4572436	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4889098	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9461534	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2833907	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4889098	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	44985	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	59113	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	ndra	Stock Dividend Payable StockDividendPayable	840	usd
CY2022	ndra	Stock Dividend Payable StockDividendPayable	7790	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	354091	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	505816	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 1 - Nature of the Business</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) has developed and is continuing to develop technology for characterizing tissue non-invasively, at the point of patient care, to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray computed tomography (“CT”), magnetic resonance imaging (“MRI”) or other technologies are unavailable or impractical.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA was incorporated on July 18, 2007 as a Delaware corporation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain reclassifications have been made to the 2022 consolidated financial statements in order to conform to the current period presentations. These classifications did not impact the net loss for the period ended December 31, 2023.</p>
CY2023	ndra	Inventory Reserve Percentage InventoryReservePercentage	0.05	pure
CY2023	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	138045	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2622865	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	354091	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	505816	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	365919	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	518147	usd
CY2023	ndra	Research And Development Expense1 ResearchAndDevelopmentExpense1	5003695	usd
CY2022	ndra	Research And Development Expense1 ResearchAndDevelopmentExpense1	6554194	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1514715	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	410358	shares
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1514715	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	410358	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	Effective January 1, 2024, the pool of shares issuable under the Omnibus Plan automatically increased by 1,717,783 shares from 1,322,169 shares to 3,039,952 shares
CY2023Q4	us-gaap	Cumulative Dividends CumulativeDividends	91930152	usd
CY2023Q4	ndra	Working Capital WorkingCapital	2129717	usd
CY2023Q4	ndra	Percentage Of Inventory Reserve PercentageOfInventoryReserve	0.05	pure
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	138045	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2622865	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2644717	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	587030	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	738720	usd
CY2023Q4	us-gaap	Development In Process DevelopmentInProcess	125151	usd
CY2022Q4	us-gaap	Development In Process DevelopmentInProcess	140617	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	600399	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	643682	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	111782	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	235655	usd
CY2023	us-gaap	Depreciation Depreciation	123726	usd
CY2022	us-gaap	Depreciation Depreciation	96661	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	360401	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	613961	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	150293	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	60638	usd
CY2023Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	35518	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	683738	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5750	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5750	usd
CY2023Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	148792	usd
CY2022Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	158925	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	700754	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1523012	usd
CY2023Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	90000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	ndra	Preferred Stock Shares Undesignated PreferredStockSharesUndesignated	9889000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10390150	shares
CY2023Q4	ndra	Stock Payable Share StockPayableShare	5233	usd
CY2021Q2	ndra	Gross Proceeds From Sales Of Common Stock GrossProceedsFromSalesOfCommonStock	6200000	usd
CY2023	ndra	Aggregate Fair Value Of Stock Options Granted AggregateFairValueOfStockOptionsGranted	1017534	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions	0	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	391902	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.47
CY2023	ndra	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P7Y4M28D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	274128	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.02
CY2023	ndra	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P8Y10M2D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	41790	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	33.89
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	624240	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.25
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M3D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	269255	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	31.41
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M2D
CY2023Q4	ndra	Restricted Common Shares Issued RestrictedCommonSharesIssued	202020	shares
CY2023Q4	ndra	Restricted Common Stock Fair Value RestrictedCommonStockFairValue	200485	usd
CY2023Q2	ndra	Warrants Shares Issued WarrantsSharesIssued	2156250	shares
CY2023Q2	ndra	Exercise Price Per Share Or Per Unit Of Warrants ExercisePricePerShareOrPerUnitOfWarrants	1.40
CY2023Q2	ndra	Expiring Date Of Warrants ExpiringDateOfWarrants	2028-05-02
CY2023Q2	ndra	Number Of Warrants Exercise Or Exercisable NumberOfWarrantsExerciseOrExercisable	301875	shares
CY2023Q2	ndra	Exercise Price Per Share Or Per Unit Of Warrants Exercisable ExercisePricePerShareOrPerUnitOfWarrantsExercisable	1.50
CY2023Q2	ndra	Expiring Date Of Warrants Exercisable ExpiringDateOfWarrantsExercisable	2026-11-02
CY2023	ndra	Total Common Stock Shares Issued TotalCommonStockSharesIssued	1583500	shares
CY2023	ndra	Gross Proceeds From Sales Of Common Stock GrossProceedsFromSalesOfCommonStock	101485900000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	202624	usd
CY2023Q4	ndra	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	202624	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	405247	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	39328	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	365919	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	173857	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	192062	usd
CY2023	ndra	Rent Expenses RentExpenses	218815	usd
CY2022	ndra	Rent Expenses RentExpenses	213912	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-8403400	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-11548400	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1593300	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1630700	usd
CY2023	us-gaap	Income Loss From Subsidiaries Before Tax IncomeLossFromSubsidiariesBeforeTax	-9996700	usd
CY2021	us-gaap	Income Loss From Subsidiaries Before Tax IncomeLossFromSubsidiariesBeforeTax	-13179100	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	ndra	Deferred Federal Income Tax Expense S Benefit DeferredFederalIncomeTaxExpenseSBenefit	0	usd
CY2022	ndra	Deferred Federal Income Tax Expense S Benefit DeferredFederalIncomeTaxExpenseSBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	ndra	Expected Tax At Statutory Rate ExpectedTaxAtStatutoryRate	-2099400	usd
CY2023	ndra	Expected Tax At Statutory Rates Percentage ExpectedTaxAtStatutoryRatesPercentage	0.21	pure
CY2022	ndra	Expected Tax At Statutory Rate ExpectedTaxAtStatutoryRate	-2767700	usd
CY2022	ndra	Expected Tax At Statutory Rates Percentage ExpectedTaxAtStatutoryRatesPercentage	0.21	pure
CY2023	ndra	Permanent Differences PermanentDifferences	-83000	usd
CY2023	ndra	Permanent Differences Percenatage PermanentDifferencesPercenatage	0.01	pure
CY2022	ndra	Permanent Differences PermanentDifferences	3000	usd
CY2022	ndra	Permanent Differences Percenatage PermanentDifferencesPercenatage	0	pure
CY2023	ndra	Deferred State And Federal Income Tax Expense Benefit DeferredStateAndFederalIncomeTaxExpenseBenefit	-448100	usd
CY2023	ndra	Effective Income Tax Rate Reconciliation State And Federal Income Taxes EffectiveIncomeTaxRateReconciliationStateAndFederalIncomeTaxes	0.04	pure
CY2022	ndra	Deferred State And Federal Income Tax Expense Benefit DeferredStateAndFederalIncomeTaxExpenseBenefit	-589200	usd
CY2022	ndra	Effective Income Tax Rate Reconciliation State And Federal Income Taxes EffectiveIncomeTaxRateReconciliationStateAndFederalIncomeTaxes	0.04	pure
CY2023	ndra	State Rate Change Federal Impact StateRateChangeFederalImpact	0	usd
CY2023	ndra	State Rate Change Federal Impact Percentage StateRateChangeFederalImpactPercentage	0	pure
CY2022	ndra	State Rate Change Federal Impact StateRateChangeFederalImpact	53200	usd
CY2022	ndra	State Rate Change Federal Impact Percentage StateRateChangeFederalImpactPercentage	0	pure
CY2023	ndra	State Rate Change Adjustment StateRateChangeAdjustment	0	usd
CY2023	ndra	State Rate Change Adjustment Percentage StateRateChangeAdjustmentPercentage	0	pure
CY2022	ndra	State Rate Change Adjustment StateRateChangeAdjustment	-253200	usd
CY2022	ndra	State Rate Change Adjustment Percentage StateRateChangeAdjustmentPercentage	0.02	pure
CY2023	ndra	Effectiveincometaxratereconciliationforeignincometaxratedifferential Effectiveincometaxratereconciliationforeignincometaxratedifferential	-33800	usd
CY2023	ndra	Effectiveincometaxratereconciliationforeignincometaxratedifferentialrate Effectiveincometaxratereconciliationforeignincometaxratedifferentialrate	0	pure
CY2022	ndra	Effectiveincometaxratereconciliationforeignincometaxratedifferential Effectiveincometaxratereconciliationforeignincometaxratedifferential	-35800	usd
CY2022	ndra	Effectiveincometaxratereconciliationforeignincometaxratedifferentialrate Effectiveincometaxratereconciliationforeignincometaxratedifferentialrate	0	pure
CY2023	ndra	Effectiveincometaxratereconciliationchangeindeferredtaxassetvaluationallowance Effectiveincometaxratereconciliationchangeindeferredtaxassetvaluationallowance	2630700	usd
CY2023	ndra	Effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance Effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance	-0.26	pure
CY2022	ndra	Effectiveincometaxratereconciliationchangeindeferredtaxassetvaluationallowance Effectiveincometaxratereconciliationchangeindeferredtaxassetvaluationallowance	5134200	usd
CY2022	ndra	Effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance Effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance	-0.39	pure
CY2023	ndra	Prior Year True Ups PriorYearTrueUps	33600	usd
CY2023	ndra	Effectiveincometaxratereconciliationotheradjustments Effectiveincometaxratereconciliationotheradjustments	0	pure
CY2022	ndra	Prior Year True Ups PriorYearTrueUps	-1544500	usd
CY2022	ndra	Effectiveincometaxratereconciliationotheradjustments Effectiveincometaxratereconciliationotheradjustments	0.12	pure
CY2023	ndra	Effective Income Tax Continuing Operations EffectiveIncomeTaxContinuingOperations	0	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	ndra	Effective Income Tax Continuing Operations EffectiveIncomeTaxContinuingOperations	0	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1406400	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1145700	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	63300	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	13100	usd
CY2023Q4	ndra	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	7800	usd
CY2022Q4	ndra	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	12500	usd
CY2023Q4	ndra	Right Of Use Assets RightOfUseAssets	-92600	usd
CY2022Q4	ndra	Right Of Use Assets RightOfUseAssets	-132300	usd
CY2023Q4	ndra	Right Of Use Liabilities RightOfUseLiabilities	95700	usd
CY2022Q4	ndra	Right Of Use Liabilities RightOfUseLiabilities	135500	usd
CY2023Q4	us-gaap	Capital Capital	1960100	usd
CY2022Q4	us-gaap	Capital Capital	1314202	usd
CY2023Q4	us-gaap	Line Of Credit LineOfCredit	29800	usd
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	29800	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1042600	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	674100	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	21162500	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	18531802	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21162500	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18531802	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5700860600000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6203353500000	usd
CY2023	ndra	Desription For The Net Loss Operation DesriptionForTheNetLossOperation	Out of the $62,033,535 net operating losses carry forward, $16,012,698 will begin to expire in 2028 and $45,990,837 will have an indefinite life
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	6760827000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	7288910300000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4425038	usd

Files In Submission

Name	View Source	Status
0001654954-24-003873-index-headers.html	Edgar Link	pending
0001654954-24-003873-index.html	Edgar Link	pending
0001654954-24-003873.txt	Edgar Link	pending
0001654954-24-003873-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ndra-20231231.xsd	Edgar Link	pending
ndra_10k.htm	Edgar Link	pending
ndra_10kimg1.jpg	Edgar Link	pending
ndra_10kimg2.jpg	Edgar Link	pending
ndra_10kimg3.jpg	Edgar Link	pending
ndra_ex1021.htm	Edgar Link	pending
ndra_ex1022.htm	Edgar Link	pending
ndra_ex1023img1.jpg	Edgar Link	pending
ndra_ex1023img2.jpg	Edgar Link	pending
ndra_ex1023img3.jpg	Edgar Link	pending
ndra_ex1023img4.jpg	Edgar Link	pending
ndra_ex1023img5.jpg	Edgar Link	pending
ndra_ex1023img6.jpg	Edgar Link	pending
ndra_ex1024img1.jpg	Edgar Link	pending
ndra_ex231.htm	Edgar Link	pending
ndra_ex232.htm	Edgar Link	pending
ndra_ex311.htm	Edgar Link	pending
ndra_ex312.htm	Edgar Link	pending
ndra_ex321.htm	Edgar Link	pending
ndra_ex97.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
ndra-20231231_cal.xml	Edgar Link	unprocessable
ndra-20231231_def.xml	Edgar Link	unprocessable
ndra-20231231_lab.xml	Edgar Link	unprocessable
ndra-20231231_pre.xml	Edgar Link	unprocessable
ndra_10k_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NDRA
ENDRA Life Sciences Inc. Stock $ndra

2024 Q1 Form 10-K Financial Statement

#000165495424003873 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NDRA ENDRA Life Sciences Inc. Stock $ndra

2024 Q1 Form 10-K Financial Statement

#000165495424003873 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NDRA
ENDRA Life Sciences Inc. Stock $ndra